Successful outcomes following anti-PD-1 therapy require DC-T cell crosstalk [102] and the initiation of anti-tumor CD8+ T cell responses by Sec22b-dependent cross-presentation in DCs [51]. This evidence concerns the gene SEC22B and neoplasm.